NFkB p105 / p50 (Ab 907) Antibody | 79-269

NFkB p105 / p50 (Ab 907) Antibody | 79-269 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: NFkB-p105/p50 (Ab-907) antibody was raised against a peptide sequence around aa.905~909 (P-L-S-P-A) derived from Human NFκB-p105.

Research Area: Apoptosis, Cancer

Tested Application: WB, IHC

Application: Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100

Specificiy: This antibody detects endogenous level of total NFκB-p105/p50 protein.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 120 kDa

Validation: N/A

Isoform: N/A

Purification: Antibodies were purified by affinity-chromatography using epitope-specific peptide.

Clonality: Polyclonal

Clone: N/A

Isotype: N/A

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+) , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Concentration: 1 mg/mL

Storage Condition: Store antibody at -20˚C for up to one year.

Alternate Name: p50, KBF1, p105, EBP-1, NF-kB1, NFKB-p50, NFkappaB, NF-kappaB, NFKB-p105, NF-kappa-B, KIAA0600, DNA-binding factor KBF1, NF-kappa-B1 p84/NF-kappa-B1 p98, NFKB1, NFkB-p50

User Note: N/A

BACKGROUND: NF-κ-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-κ-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively.